论文部分内容阅读
目的评估进展期胃癌患者新辅助化疗后手术的临床疗效。方法选择进展期胃癌患者52例分为常规手术组(26例)和新辅助化疗组(26例),新辅助化疗组患者进行2个周期的FOLFOX方案化疗,再进行手术治疗。结果常规手术组肿瘤切除率为84.6%(22/26),根治性切除率为46.2%(12/26);新辅助化疗组肿瘤切除率为92.3%(24/26),根治性切除率为69.2%(18/26)。两组均无手术死亡病例,并发症发生率差异无统计学意义。结论进展期胃癌患者进行新辅助化疗可以提高手术根治率和切除率。
Objective To evaluate the clinical efficacy of neoadjuvant chemotherapy in patients with advanced gastric cancer. Methods Fifty-two patients with advanced gastric cancer were divided into two groups: conventional surgery group (n = 26) and neoadjuvant chemotherapy group (n = 26). Neoadjuvant chemotherapy group received two cycles of FOLFOX regimen and then surgery. Results The tumor resection rate was 84.6% (22/26) in radical resection group and 46.2% (12/26) in radical resection group. The resection rate was 92.3% (24/26) in neoadjuvant chemotherapy group, and the radical resection rate was 69.2% (18/26). No surgical deaths were found in both groups, with no significant difference in the incidence of complications. Conclusion Neoadjuvant chemotherapy in patients with advanced gastric cancer can improve the cure rate and resection rate.